Tongli Bio completed tens of millions of yuan of financing to promote the clinical development of high-efficiency broad-spectrum anti-human and veterinary infectious diseases new drugs.

Introduction: Tyger Pharmaceuticals leads the way in clinical trials and industry-scaled production of the candidate drug "TL-010".
Suzhou Tongli Biopharmaceutical Co., Ltd. (Suzhou Tongli Biopharmaceutical Co., Ltd.) recently announced the completion of a new round of financing, led exclusively by Tagg Pharmaceuticals' Hangzhou Tagg Equity Investment Partnership, Tianchao Capital as the financial advisor of the current round of financing.
financing is mainly used to promote the company's anti-human throbacter disease candidate drug "TL-010" clinical trials and industrialization to enlarge production.
, Tongli Bio completed the first round of financing of 10 million yuan in 2017, co-financed by Shanghai Investment Management Center and Taifu Capital.
is a high-tech enterprise dedicated to biomedical innovation, research and development and product transformation.
since its inception in 2012, the company has focused on developing treatment products that pose a serious threat to global public health from zoonotic infectious diseases.
Tongli fully independent research and development of the flagship product TL-010 has completed the preclinical pharmaceutical evaluation, raw materials and tablets process optimization and clinical batch production, and in China, the United States and other countries to apply for and obtain a number of invention patents.
has been approved by the U.S. and South African Drug Administrations for the clinical application for TL-010 new drugs, and successfully launched and completed the International Clinical Phase I trial of new drugs in 2019.
Currently, the company plans to actively seek business partners and manufacturers to jointly develop, it is expected that through the FDA 505 (b)(2) simplified clinical research and development path and approval channels, accelerate the TL-010 in the United States, China and other countries to declare the listing and enter the WHO core drug list.
usually refers to a range of diseases caused by parasites, bacteria or viruses.
Who estimates that there are more than 17 commonly neglected tropical infectious diseases worldwide, including schistosomiasis, food-based parasitic diseases (hepatosomiasis, pulmonary sepsis, cystic disease, etc.), as well as aphids and echinococcus diseases, in nearly 100 tropical and subtropical countries around the world, affecting approximately 1.4 billion people.
Among them, schistosomiasis is infected by skin contact with water sources in affected areas containing larvae, such as water for domestic use and secondary disasters of floods, which can induce chronic anemia and inflammation, seriously affecting the physical development of children and adolescents and causing physical and mental disabilities.
Food-sourced insect-sucking diseases, including liver-sucking disease and pulmonary sucker disease, are infected by eating raw fish or half-born, poorly processed freshwater fish such as "fish raw" and crabs, and are the most important food-eating human-animal diseases.
20 million people are infected worldwide, mainly in Guangdong, Guangxi and Southeast Asia, including Vietnam, Thailand, South Korea and the Russian Far East.
is now clear, liver sucker belongs to the class I bio-carcinogenic, chronic infection can be induced as liver bile tube cancer.
In addition, encapssis is caused by echinococcus ticks in humans or animals such as dogs caused by zoonasomal parasitic diseases, dogs as the main source of infection, people and cattle and sheep and other animals are intermediate hosts.
long incubation period, high fatality rate, also known as "worm cancer."
more than half of the 200,000 new cases of the disease each year occur in northwest China.
Especially in recent years, with the transformation of urbanization, modern lifestyle changes and years of flooding, some urbanites can also become infected through easily overlooked transmission routes such as eating unclean fresh aquatic products and meat, exposure to pets and diseased water.
In view of the fact that innovative drugs for these diseases have been rare over the past 30 years, the World Health Organization and the United States Food and Drug Administration have in recent years classified them as neglected tropical infectious diseases and have developed preferential policies and fast-track declaration channels to encourage pharmaceutical companies to develop innovative drugs to treat these neglected tropical infectious diseases.
TL-010, which is owned by Tonant Bio, was approved by the FDA in June 2017 for the treatment of schistosomiasis.
Qian Ming-chen, founder of Tongli Bio, graduated from the Department of Clinical Medicine of Chongqing Medical College in 1988 and obtained his M.D. from the first batch of infectious disease doctoral points in China and the clinical pharmacology base of infectious diseases of the Ministry of Health.
in his Ph.D., he has done a series of chemical, pharmacological and clinical trials on anti-infectant drugs such as schistosomiasis.
Then stay in the United States to complete postdoctoral training in pharmacy, has worked in Shi Guibao, Genentek and other multinational pharmaceutical companies drug discovery, preclinical and clinical pharmacology departments, involved in a variety of large and small molecular drug research and development and declaration of market.
2008, Dr. Qian Mingshing returned to China to participate in the formation of Shanghai Smart Chemistry Preclinical Department, and served as Vice President.
In understanding the high incidence of schistosomiasis worldwide, the fact that hundreds of millions of patients are still short of medical care and medicines, and the World Health Organization's call for better drugs to control and eliminate such tropical infectious diseases, with the support of angel investors, the creation of Tongli Bio, focusing on the development of TL-010, aimed at solving the existing market drug medical compliance, production process pollution and global supply shortage through green bioenzyme chemistry combination technology. Dr. Qian Mingshing,
, said, "The results of clinical trials show that TL-010 tablets are orally convenient, safe, have the expected dynamic behavior of primary and metabolic objects, and have a clinical advantage over listed drugs, which is an important milestone in the company's global development of TL-010."
We will work with domestic and foreign pharmaceutical companies and CDMO interested in entering high-standard international markets to complete the enlarged production, process validation and necessary simplified clinical trials of pre-market commercialization batches within 2 years, in accordance with the requirements of the FDA Orphan Drug Qualification and 505(b)(2) Development Path to accelerate the declaration channel.
expected to go public, it can be approved by the WHO, included in the WHO basic drug list and for multi-country procurement.
"We believe that TL-010 can be widely used in the treatment of various types of schistosomiasis and food-based schistosomiasis, to make up for the current global shortage of drugs for the prevention and treatment of such patients, it is possible to become the best treatment of schistosomiasis and other parasitic diseases in the 21st century, for the benefit of poor patients."
not only have certain economic benefits, but also has obvious social benefits of public health prevention and control and the influence of international brands.
We are honored to receive recognition and investment from the Tiger Pharmaceuticals Investment Team in this round of financing, which reflects Tiger Pharmaceuticals' reputation, experience and ability in the industry, its unique focus on sustainable development goals and corporate social responsibility, and its active participation in supporting the resolution of global public health imbalances, and in identifying and investing in innovative clinically valuable medical products and businesses.
" At present, Tongli Bio has formed a team of professional research and development team and academic consultants with a global perspective, in addition to in-depth work and layout in the field of diagnosis and control of human and veterinary infectious diseases, actively seeking commercial production partners of post-market API and tablets, but also plans to further financing and Business cooperation, based on existing differentiated product pipelines to expand and extend, actively explore and enter other characteristic sub-circuits such as biomarkers and infectious disease molecular diagnosis and animal health field - broad-spectrum veterinary insect repellent development, etc., to provide global public health and less developed countries unsuperfed clinical needs of diagnostic products solutions.
About Tiger Pharmaceuticals Tyger Pharmaceuticals (stock code GEM: 300347, H shares: 03347) is a contract research organization (CRO) focused on providing clinical trial-wide professional services for new drug research and development, providing comprehensive clinical research services and solutions for pharmaceutical and medical device innovation enterprises worldwide, reducing research and development risks, shortening research and development cycle, saving research and development funds, promoting the process of product marketization, so that patients can use newer and better medical and medical products at an early date.
about Tianchao Capital Is a boutique investment bank focused on the healthcare sector, providing investment banking services such as equity financing, mergers and acquisitions, divestitures, licensed joint ventures, cross-border transactions, etc.
company has always pursued value exploration, value creation, focus on technology or model breakthrough high-quality enterprises, serving the "competition of nature, beyond the limit" of the enterprise.
established, has 10 customers, the service area covers new drug research and development, medical devices, medical diagnostics, high-value supplies, medical services, emerging technologies, etc. , the total amount of services more than billions of yuan or equivalent.
As a link capital and high-quality enterprises, domestic and international bridges, Tianchao Capital is determined to seek capital, technology, partners and other resources for enterprises in the world through professional, dedicated, high-quality, efficient services, to promote the rapid development of enterprises.
.